Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for secondary sclerosing cholangitis has been reported in the published literature.
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
35 publications have been identified in PubMed for secondary sclerosing cholangitis. Research spans Case Report / Case Series (46%), Review / Meta-Analysis (31%), and Epidemiology / Natural History (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 16 | 46% |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 6:09 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries |
11 |
31% |
Disease patterns and progression | 4 | 11% |
Laboratory research | 2 | 6% |
Other research | 1 | 3% |
Testing and diagnosis research | 1 | 3% |
Teschke R (2026). [PMID: 42123570](https://pubmed.ncbi.nlm.nih.gov/42123570/). *Int J Mol Sci*. [Review / Meta-Analysis]
Unknown (2026). [PMID: 41694629](https://pubmed.ncbi.nlm.nih.gov/41694629/). *Clin Case Rep*. [Other]
Husain KH (2026). [PMID: 42199379](https://pubmed.ncbi.nlm.nih.gov/42199379/). *ACG Case Rep J*. [Case Report / Case Series]
Wang C (2026). [PMID: 42117555](https://pubmed.ncbi.nlm.nih.gov/42117555/). *J Infect Dis*. [Epidemiology / Natural History]
Krasnenkova SF (2026). [PMID: 41989543](https://pubmed.ncbi.nlm.nih.gov/41989543/). *Arkh Patol*. [Epidemiology / Natural History]
Däniker M (2026). [PMID: 41170802](https://pubmed.ncbi.nlm.nih.gov/41170802/). *Pediatr Dev Pathol*. [Review / Meta-Analysis]
Wang Q (2026). [PMID: 40466976](https://pubmed.ncbi.nlm.nih.gov/40466976/). *Gastroenterology*. [Case Report / Case Series]
Agarwal D (2026). [PMID: 41885964](https://pubmed.ncbi.nlm.nih.gov/41885964/). *Abdom Radiol (NY)*. [Review / Meta-Analysis]
Agrawal R (2026). [PMID: 41902447](https://pubmed.ncbi.nlm.nih.gov/41902447/). *Histopathology*. [Case Report / Case Series]
Björnsson ES (2026). [PMID: 42092331](https://pubmed.ncbi.nlm.nih.gov/42092331/). *J Intern Med*. [Review / Meta-Analysis]
AI-curated news mentioning secondary sclerosing cholangitis
Updated Jun 12, 2026
A study published in PubMed explores the use of salvage tacrolimus therapy for patients with steroid-refractory immune-related adverse event-associated sclerosing cholangitis. This research highlights a potential treatment avenue for a challenging condition often seen in cancer immunotherapy.